Shots:

• The P-III FeDeriCa study involves assessing of SC inj. of Perjeta + Herceptin + CT vs IV infusion of Perjeta + Herceptin + CT in 500 patients with HER2+ who are being treated in the neoadjuvant and adjuvant setting
• The P-III FeDeriCa study results: met its 1EP & 2EPs i.e- minimum levels of Perjeta & Herceptin in the blood during a given dosing interval (C_trough); the rate of pCR (59.7% vs 59.5%); no new safety signals were identified with no difference in cardiac toxicity respectively
• The FDC of Perjeta and Herceptin is a new SC formulation combining the Perjeta and Herceptin with Halozyme’s Enhanze drug delivery technology- administered under the skin in just minutes compared to hours with IV administration thus reducing the time spent in receiving treatment

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche